Toyonaka-city, Japan Clinical Trials

A listing of Toyonaka-city, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD). Phase 2: To evaluate the efficacy of efavaleukin alfa in subjects with steroid refractory cGVHD as measured by overall response rate (ORR) at 16 …

Research Site
 (9.5 away) Contact site
  • 12 views
  • 12 Jun, 2021
  • +28 other locations
A Study of AZD8233 in Participants With Dyslipidemia.

A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A and Part B. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a randomized, double-blind, placebo-controlled, …

Research Site
 (4.1 away) Contact site
  • 0 views
  • 07 May, 2021
  • +1 other locations
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor …

Eisai Trial Site #17
 (3.0 away) Contact site
  • 2 views
  • 06 Apr, 2021
  • +16 other locations
A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

kidney function test
ret inhibitor
solid tumour
systemic therapy
renal function
Osaka City General Hospital
 (6.0 away) Contact site
  • 1244 views
  • 20 Jun, 2021
  • +158 other locations
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. …

solid tumor
breast cancer
metastatic solid tumor
primary cancer
metastasis
Osaka City Hospital Organization Osaka City General Hospital
 (6.0 away) Contact site
  • 0 views
  • 20 Jun, 2021
  • +71 other locations
A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the …

dexamethasone
bone marrow procedure
cell transplantation
carfilzomib
serum calcium
Osaka City University Hospital
 (9.5 away) Contact site
  • 0 views
  • 14 May, 2021
  • +78 other locations
A Phase 1/2 Study Evaluating the Safety Tolerability PK and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Research Site
 (7.2 away) Contact site
  • 472 views
  • 19 Jun, 2021
  • +282 other locations
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF) Post-polycythemia Vera Myelofibrosis (Post-PV MF) or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 1/2 multicenter, single arm, open-label study in Japanese subjects with DIPSS intermediate or high-risk PMF, …

Osaka City University Hospital
 (9.5 away) Contact site
  • 0 views
  • 27 Feb, 2021
  • +15 other locations
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

The purpose of phase 1 part in this study is to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase …

cytarabine
consolidation therapy
neoadjuvant therapy
flt3 internal tandem duplication
idarubicin
Site JP81019
 (6.3 away) Contact site
  • 10 views
  • 17 Jun, 2021
  • +58 other locations
A Study Investigating the Safety Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

The purpose of this study is to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517. This study will also evaluate the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.

remission
secondary acute myeloid leukemia
hydroxyurea
induction chemotherapy
refractory acute myeloid leukemia (aml)
Site JP81011
 (6.3 away) Contact site
  • 5 views
  • 20 Jun, 2021
  • +10 other locations